• This record comes from PubMed

An engineered retroviral proteinase from myeloblastosis associated virus acquires pH dependence and substrate specificity of the HIV-1 proteinase

. 1992 Mar ; 11 (3) : 1141-4.

Language English Country Great Britain, England Media print

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/pmid01547777

In an attempt to understand the structural reasons for differences in specificity and activity of proteinases from two retroviruses encoded by human immunodeficiency virus (HIV) and myeloblastosis associated virus (MAV), we mutated five key residues predicted to form part of the enzyme subsites S1, S2 and S3 in the substrate binding cleft of the wild-type MAV proteinase wMAV PR. These were changed to the residues occupying a similar or identical position in the HIV-1 enzyme. The resultant mutated MAV proteinase (mMAV PR) exhibits increased enzymatic activity, altered substrate specificity, a substantially changed pH activity profile and a higher pH stability close to that observed in the HIV-1 PR. This dramatic alteration of MAV PR activity achieved by site-directed mutagenesis suggests that we have identified the amino acid residues contributing substantially to the differences between MAV and HIV-1 proteinases.

See more in PubMed

FEBS Lett. 1990 Jul 30;268(1):35-8 PubMed

J Biol Chem. 1989 Feb 25;264(6):3428-35 PubMed

Nature. 1989 Nov 16;342(6247):299-302 PubMed

Annu Rev Biochem. 1988;57:701-54 PubMed

FEBS Lett. 1991 Apr 22;282(1):73-6 PubMed

Biochemistry. 1990 Jun 26;29(25):5889-98 PubMed

Biochemistry. 1991 Apr 9;30(14):3437-43 PubMed

Biochim Biophys Acta. 1990 Jan 30;1048(1):1-18 PubMed

Science. 1989 Aug 11;245(4918):616-21 PubMed

Science. 1989 Dec 1;246(4934):1149-52 PubMed

FEBS Lett. 1988 Sep 12;237(1-2):187-90 PubMed

Biochem Biophys Res Commun. 1967 Apr 20;27(2):157-62 PubMed

Science. 1990 Apr 20;248(4953):358-61 PubMed

Find record

Citation metrics

Archiving options